A
1.92
-0.05 (-2.54%)
| Previous Close | 1.97 |
| Open | 1.96 |
| Volume | 1,595,744 |
| Avg. Volume (3M) | 1,226,268 |
| Market Cap | 81,680,384 |
| Price / Book | 26.26 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.24 |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -22.96 M |
| Levered Free Cash Flow (TTM) | -13.95 M |
| Return on Assets (TTM) | -91.05% |
| Return on Equity (TTM) | -280.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Annovis Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
1.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.69% |
| % Held by Institutions | 16.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merit Financial Group, Llc | 31 Mar 2026 | 81,316 |
| Group One Trading Llc | 31 Mar 2026 | 69,663 |
| Sherry Group, Inc. | 31 Mar 2026 | 57,270 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |